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Abstract
Colon Cancer is notorious for its high mortality rates in the US.
Sepsis, bacterial infection, is prominent among the colorectal cancer
population. One factor commonly considered for the rise of sepsis is
the harsh side effects of chemotherapy drugs. However, many
undermine the effects of chemotherapy on the diversity of the gut
microbiome, which are microbial communities within a system. This
past year I have completed phase one of my project where I have
developed the relationship between the 4 chemotherapeutics effect
on the microbiome. The next phase of my experiments is to integrate
probiotics, beneficial bacteria, to potentially remediate the effects
caused by chemo and lower chances of contracting sepsis. This will
be done using DNA extraction, 16sRNA amplification, and Illumina
sequencing to compare our communities pre and post treatment. Its
predicted that adding probiotics can mitigate changes in post
treatment groups and potentially restore diversity. Overall implication
is that gut microbiota are critical to the development of personalized
cancer treatment and predicting chances of contracting sepsis among
patients; understanding the drug-host relationship can help make
better predictions for potential infections during treatment.
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• For all drug treatments, the 48 hour samples gave the
highest reading for DNA compared to the 24 and 72
hour.
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Hypothesis
When comparing to pre-treatment microbiome, we expect that
administering dose dependent treatment of Cisplatin and Capecitabine to
microbial communities over time will alter the microbiome, reducing the
abundance of some taxa, while increasing the abundance of others
(likely by simply allowing them to proliferate).
We also expect that adding probiotics (Lactobacillus; longum, and
rhamnosus ) to post treatment microbial communities can help mitigate
changes to the community and possibly diminish the effects of
chemotherapy.

• Based on initial trials of testing viability of colonies,
there was no significant difference in bacterial growth
in terms of time dependence
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• Analyze data from 16s Sequencing and send the
samples to Sanger sequencing
• Integrate common probiotic and understand the
mechanism with and without the presence of
drugs
• Use synergistic treatments to see effect on the
microbiome
• Extend the research to other microbiomes other
than the gut à Skin, gut brain axis
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